128 related articles for article (PubMed ID: 30723304)
1. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Olopade OI; Eisen A; Lerner-Ellis J; Snyder C; Kim SJ; Sun P; Narod SA
Br J Cancer; 2019 Feb; 120(4):398-403. PubMed ID: 30723304
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
Jonasson JG; Stefansson OA; Johannsson OT; Sigurdsson H; Agnarsson BA; Olafsdottir GH; Alexiusdottir KK; Stefansdottir H; Munoz Mitev R; Olafsdottir K; Olafsdottir K; Arason A; Stefansdottir V; Olafsdottir EJ; Barkardottir RB; Eyfjord JE; Narod SA; Tryggvadóttir L
Br J Cancer; 2016 Sep; 115(7):776-83. PubMed ID: 27537391
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
Olafsdottir EJ; Borg A; Jensen MB; Gerdes AM; Johansson ALV; Barkardottir RB; Johannsson OT; Ejlertsen B; Sønderstrup IMH; Hovig E; Lænkholm AV; Hansen TVO; Olafsdottir GH; Rossing M; Jonasson JG; Sigurdsson S; Loman N; Nilsson MP; Narod SA; Tryggvadottir L
Br J Cancer; 2020 Nov; 123(11):1608-1615. PubMed ID: 32939053
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
Foulkes WD; Metcalfe K; Sun P; Hanna WM; Lynch HT; Ghadirian P; Tung N; Olopade OI; Weber BL; McLennan J; Olivotto IA; Bégin LR; Narod SA
Clin Cancer Res; 2004 Mar; 10(6):2029-34. PubMed ID: 15041722
[TBL] [Abstract][Full Text] [Related]
6. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
Tryggvadottir L; Olafsdottir EJ; Olafsdottir GH; Sigurdsson H; Johannsson OT; Bjorgvinsson E; Alexiusdottir K; Stefansson OA; Agnarsson BA; Narod SA; Eyfjord JE; Jonasson JG
Breast Cancer Res Treat; 2013 Jul; 140(2):375-84. PubMed ID: 23857704
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
[TBL] [Abstract][Full Text] [Related]
8. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen receptors revisited: long-term follow up of over five thousand breast cancer patients.
Hähnel R; Spilsbury K
ANZ J Surg; 2004 Nov; 74(11):957-60. PubMed ID: 15550082
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.
King MC; Wieand S; Hale K; Lee M; Walsh T; Owens K; Tait J; Ford L; Dunn BK; Costantino J; Wickerham L; Wolmark N; Fisher B;
JAMA; 2001 Nov; 286(18):2251-6. PubMed ID: 11710890
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
14. A comparison of bilateral breast cancers in BRCA carriers.
Weitzel JN; Robson M; Pasini B; Manoukian S; Stoppa-Lyonnet D; Lynch HT; McLennan J; Foulkes WD; Wagner T; Tung N; Ghadirian P; Olopade O; Isaacs C; Kim-Sing C; Møller P; Neuhausen SL; Metcalfe K; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1534-8. PubMed ID: 15941968
[TBL] [Abstract][Full Text] [Related]
15. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
17. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
18. Body weight correlates with mortality in early-stage breast cancer.
Enger SM; Greif JM; Polikoff J; Press M
Arch Surg; 2004 Sep; 139(9):954-58; discussion 958-60. PubMed ID: 15381612
[TBL] [Abstract][Full Text] [Related]
19. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Brown LA; Johnson K; Leung S; Bismar TA; Benítez J; Foulkes WD; Huntsman DG
Breast Cancer Res Treat; 2010 Jun; 121(2):347-54. PubMed ID: 19636701
[TBL] [Abstract][Full Text] [Related]
20. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; van den Ouweland A; van Geel B; Brekelmans CT; Klijn JG
Breast Cancer Res Treat; 2008 Sep; 111(2):303-11. PubMed ID: 17952592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
